NCT03203616View on ClinicalTrials.gov

Kadcyla In pAtients With bRAin Metastasis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 23, 2018

Primary Completion Date

August 27, 2018

Study Completion Date

August 27, 2018

Conditions
Metastatic HER2-positive Breast Cancer With Brain Metastasis
Interventions
DRUG

KADCYLA 160 MG Injection

Kadcyla 160Mg Powder for Injection: 3.6 mg/kg iv every 3 weeks

Sponsors
All Listed Sponsors
lead

Jules Bordet Institute

OTHER